Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Intra-articular 2.5% polyacrylamide hydrogel for the treatment of knee osteoarthritis: an observational proof-of-concept cohort study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Imaging in peripheral and axial psoriatic arthritis: contributions to diagnosis, follow-up, prognosis and knowledge of pathogenesis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Ultrasonography in gout: utility in diagnosis and monitoring

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Update on imaging in rheumatic diseases

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. ABILITY OF MAGNETIC RESONANCE IMAGING TO PREDICT REMISSION AND RELAPSE IN PERIPHERAL SPONDYLOARTHRITIS

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  1. Early occupational intervention for people with low back pain in physically demanding jobs: A randomized clinical trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Hand exercise for women with rheumatoid arthritis and decreased hand function: an exploratory randomized controlled trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Placebo: den mindst skadelige behandling ved artrose?

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVES: There is a drought of effective treatments of knee osteoarthritis (OA) and new therapies are needed. The present study has been conducted to establish an initial estimate of effectiveness of intra-articular (IA) injection of a proprietary 2.5% cross-linked polyacrylamide hydrogel (PAAG) for the treatment of knee OA symptoms and signs.

METHODS: Patients with knee OA were invited into a prospective open-label cohort study. The patients received up to two IA injections of 3 ml of PAAG 1 month apart. The WOMAC questionnaire was used to estimate effectiveness, and was collected at baseline and after 4, 7 and 13 months. Primary outcome was change from baseline for the WOMAC pain subscale after 4 months (Normalised to 0-100 points; 100 worst). Data was analysed using a mixed-effect model without imputation of missing data.

RESULTS: 84 patients (48 females) received IA PAAG. Of these WOMAC data were available from 62 after 4 months, 59 after 7 months, and 56 after 13 months. There were statistically and clinically significant reductions in WOMAC pain after 4 months (mean change -14.6 points [95% CI: -18.9 to -10.2]; p<.0001). Similar results were found in WOMAC stiffness, physical function, and WOMAC total. The improvement was sustained throughout the observation period.

CONCLUSIONS: These results suggest beneficial effects of IA injection of PAAG on knee OA symptoms, even in the long term (1 year). This initial estimation of effectiveness is promising but needs to be confirmed in a randomised study with adequate measures taken to reduce risk of bias.

Original languageEnglish
JournalClinical and Experimental Rheumatology
ISSN0392-856X
Publication statusPublished - Nov 2018

ID: 55127503